EORTC QLQ-C30中文版测定卵巢癌患者生存质量的评价

An evaluation of Chinese version of EORTC QLQ-C30 for use in ovarian cancer patients

目的:对用欧洲癌症研究与治疗组织生存质量问卷第3版(EORTC QLQ-C30 V3.0)简体中文版测定我国卵巢癌患者生存质量的心理测量学特性进行考评,为卵巢癌患者的生存质量评价提供依据。方法:采用调查问卷方式,应用EORTC QLQ-C30 V3.0中文版,对2002年1月—2005年12月在北京协和医院就诊的卵巢癌化疗期、恢复期患者各60例进行生存质量测定,并以60例健康妇女作为对照,考评该量表测定卵巢癌患者生存质量的信度和效度。结果:量表的重测信度相关系数r在各个领域均为0.8以上。内部一致性信度的克朗巴赫系数α均在0.8以上。主成分分析显示中文版量表与英文版量表的结构符合。方差分析显示量表能够很好地区分不同组别妇女的生存质量。卵巢癌化疗组在不同领域的生存质量均显著低于恢复组和健康组(P<0.001)。卵巢癌恢复组整体健康状况、躯体功能、角色功能、情绪功能和社会功能评分仍较健康组低(P<0.001),乏力症状和经济领域评分也较健康组有显著差异(P<0.001)。结论:EORTC QLQ-C30 V3.0简体中文版具有良好的信度和效度,可作为我国卵巢癌患者生存质量的测评工具。

Objective： To evaluate the psychometric properties of the Chinese version of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire （EORTC QLQ-C30 V3.0） used among Chinese ovarian cancer patients. Method： Chinese version of EORTC QLQ-C30 V3.0 was completed by 60 ovarian cancer patients during chemotherapy and 60 patients during follow-up at Beijing Union Hospital from Jan,2002 to Dec, 2005. Sixty healthy women filling the questionnaires were taken as control group. The reliability and validity of the questionnaire was evaluated by QOL data measured from women in the three groups. Result：The test-retest reliability coefficients in all scales were above 0.8. Cronbach＇s alpha coefficients in each scales were also higher than 0.8. Principal component analysis revealed that the questionnaire had good construct valididy. One-Way ANOVA showed the questionnaire was able to discriminate the QOL among different groups. The results showed that in every scales women in chemotherapy group had significantly low QOL as compared to beth those in follow-up group and those in healthy group （P〈0.001）. Women in follow-up group had significantly lower scores of global health status as well as physical,role,emotional,social function （P〈0.001）, and significantly higher scores of fatigue and financial problem than in healthy group （P〈0.001）. Conclusion： Chinese version of EORTC QLQ-C30 V3.0 has proven to be reliable and valid measurement of the quality of life in Chinese ovarian cancer patients.